Question · asked by 1 review
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs MEDIUM DOSE (401 mg/day to 800 mg/day): Global state: no improvement ‐ short term
- Population
- patients with schizophrenia
- Intervention
- CHLORPROMAZINE LOW DOSE (≤ 400 mg/day)
- Comparison
- MEDIUM DOSE (401 mg/day to 800 mg/day)
- Outcome
- Global state: no improvement ‐ short term
It is very uncertain whether CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) changes global state: no improvement ‐ short term compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs MEDIUM DOSE (401 mg/day to 800 mg/day) Global state: no improvement ‐ short term · people with schizophrenia It is very uncertain whether CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) changes global state: no improvement ‐ short term compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (very low certainty). Chlorpromazine dose for people with schizophrenia (2017) · Cochrane Headline outcomes only | RR 0.83 [0.28, 2.44] | 1 study · 60 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Chlorpromazine dose for people with schizophrenia 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.